Perthera, a market leader in Precision Oncology, and The Side-Out Foundation, a not-for-profit organization focused on advancing clinical research in breast cancer, have forged a comprehensive partnership to deliver precision medicine and personalized treatment recommendations to physicians and patients throughout the country. Together, Perthera and Side-Out are launching a national clinical study program to improve outcomes for patients with advanced breast cancer, demonstrate the impact of precision oncology and accelerate clinical trial enrollment across the nation, to advance medicine & science through groundbreaking research publications.
The new partnership will give oncologists who use Perthera access to the world’s only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once. Perthera will serve as Theralink’s CRO to help bring in and enroll oncology practices in Theralink’s TRACE program, as well as provide treatment matching services to Theralink’s oncology partners.
The collaborative effort will deliver molecular profiling, personalized treatment recommendations, and clinical trial matching to patients with colorectal cancer.
GenomeWeb interviews Perthera CEO Gary Gregory and CMO Mike Pishvaian about the Perthera Platform’s proven results, the capabilities of Perthera’s molecular tumor board, and how precision medicine is changing the landscape of cancer care today.
This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients. Patients who receive precision medicine live an average of one year longer than those who do not.
Perthera and Lazarex are matching and enrolling patients in clinical trials through Lazarex’s IMPACT and CARE programs, by utilizing Perthera’s treatment-matching Artificial Intelligence (AI) technology to advance precision medicine for cancer patients.
Perthera CEO Gary Gregory talks with DocWire News to explain how Perthera’s Precision Oncology Platform is transforming precision medicine in healthcare today, with proven results and advanced technology.
Perthera, University of Virginia Health System (UVA) and Eastern Virginia Medical School (EVMS) Awarded $500,000 by Virginia Catalyst Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
Molecular tumor profiling, which enables physicians to match patients to targeted therapies, is on the rise. Read the latest report published in the British Journal of Cancer.
Initial results from the KYT program demonstrated that 27% of pancreatic cancer patients harbor highly actionable molecular alterations, defined as biomarkers that predict for a high response rate to appropriately targeted therapies.
Mr. Gregory is an experienced CEO and Board Member with 30 years of progressively challenging responsibilities in the MedTech Sector. His experience spans numerous companies and positions, including Executive Officer roles across several successful start-up companies, and leadership roles in Fortune 250 companies.
Dr. Mike Pishvaian discusses results from Perthera and PanCAN’s Know Your Tumor study, presented as Abstract 191 at ASCO GI 2019 in San Francisco, CA.